205 related articles for article (PubMed ID: 32888168)
1. COVİD-19 infection in a membranous nephropathy patient treated with rituximab.
Elcioglu OC; Artan AS; Mirioglu S; Gursu M; Durdu B; Meric Koc M; Okyaltirik F; Gultekin MA; Kazancioglu R
CEN Case Rep; 2021 Feb; 10(1):83-87. PubMed ID: 32888168
[TBL] [Abstract][Full Text] [Related]
2. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
Front Immunol; 2021; 12():738788. PubMed ID: 34721403
[TBL] [Abstract][Full Text] [Related]
3. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
4. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
Fervenza FC; Canetta PA; Barbour SJ; Lafayette RA; Rovin BH; Aslam N; Hladunewich MA; Irazabal MV; Sethi S; Gipson DS; Reich HN; Brenchley P; Kretzler M; Radhakrishnan J; Hebert LA; Gipson PE; Thomas LF; McCarthy ET; Appel GB; Jefferson JA; Eirin A; Lieske JC; Hogan MC; Greene EL; Dillon JJ; Leung N; Sedor JR; Rizk DV; Blumenthal SS; Lasic LB; Juncos LA; Green DF; Simon J; Sussman AN; Philibert D; Cattran DC;
Nephron; 2015; 130(3):159-68. PubMed ID: 26087670
[TBL] [Abstract][Full Text] [Related]
6. Membranous nephropathy after a recent SARS-CoV-2 infection.
Mateus C; Theias Manso R; Martins AR; Branco PQ
BMJ Case Rep; 2023 Jan; 16(1):. PubMed ID: 36707097
[TBL] [Abstract][Full Text] [Related]
7. Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience.
Katsuno T; Ozaki T; Kim H; Kato N; Suzuki Y; Akiyama S; Ishimoto T; Kosugi T; Tsuboi N; Ito Y; Maruyama S
Intern Med; 2017; 56(13):1679-1686. PubMed ID: 28674357
[TBL] [Abstract][Full Text] [Related]
8. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
[No Abstract] [Full Text] [Related]
9. Pharmacological treatment of primary membranous nephropathy in 2016.
van de Logt AE; Hofstra JM; Wetzels JF
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1463-1478. PubMed ID: 27535699
[TBL] [Abstract][Full Text] [Related]
10. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
[TBL] [Abstract][Full Text] [Related]
11. An overview of immunosuppressive therapy in idiopathic membranous nephropathy.
Maas R; Hofstra JM; Wetzels JF
Minerva Med; 2012 Aug; 103(4):253-66. PubMed ID: 22805618
[TBL] [Abstract][Full Text] [Related]
12. New-Onset and Relapsed Membranous Nephropathy post SARS-CoV-2 and COVID-19 Vaccination.
Ma Q; Li X; Xu G
Viruses; 2022 Sep; 14(10):. PubMed ID: 36298697
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
Lu W; Gong S; Li J; Luo H; Wang Y
Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
[TBL] [Abstract][Full Text] [Related]
14. Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population.
Anjum N; Nabi Z; Alam MA
J Ayub Med Coll Abbottabad; 2019; 31(2):265-268. PubMed ID: 31094128
[TBL] [Abstract][Full Text] [Related]
15. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab.
Rosenzwajg M; Languille E; Debiec H; Hygino J; Dahan K; Simon T; Klatzmann D; Ronco P
Kidney Int; 2017 Jul; 92(1):227-237. PubMed ID: 28318628
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib as a Novel Approach to Early Recurrent Membranous Glomerulonephritis After Kidney Transplant Refractory to Combined Conventional Rituximab Therapy.
Barbari A; Chehadi R; Kfoury Assouf H; Kamel G; Jaafar M; Abdallah A; Rizk S; Masri M
Exp Clin Transplant; 2017 Jun; 15(3):350-354. PubMed ID: 28367758
[TBL] [Abstract][Full Text] [Related]
17. Successful management of visceral disseminated varicella zoster virus infection during treatment of membranous nephropathy: a case report.
Furuto Y; Kawamura M; Namikawa A; Takahashi H; Shibuya Y
BMC Infect Dis; 2019 Jul; 19(1):625. PubMed ID: 31307420
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rituximab therapy for membranous nephropathy: a meta-analysis.
Zhang J; Bian L; Ma FZ; Jia Y; Lin P
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):8021-8029. PubMed ID: 30536351
[TBL] [Abstract][Full Text] [Related]
19. Novel treatment options in rituximab-resistant membranous nephropathy patients.
Ahmadian E; Khatibi SMH; Vahed SZ; Ardalan M
Int Immunopharmacol; 2022 Jun; 107():108635. PubMed ID: 35240381
[TBL] [Abstract][Full Text] [Related]
20. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
